Corbus Pharmaceuticals Stock (NASDAQ: CRBP)

Dernières nouvelles pour Corbus Pharmaceuticals (NASDAQ:CRBP) Stock

CORBUS PHARMACEUTICALS HOLDI

Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals Holdings Inc

It&#8217;s been a roller coaster year for Wall Street as investors revise expectations during a period of <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45435725/tariffs-slow-retail-spending-as-producer-prices-post-sharpest-drop-since-2020">rapidly changing policy announcements</a> in the White House. While markets turned bearish in March and April as the Trump Administration threatened tariffs on several U.S. trade partners, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) retraced some of its losses as the administration backed off some of its policy commitments and <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45376487/wall-street-edges-higher-as-inflation-cools-nasdaq-100-hits-10-week-highs">economic indicators look promising</a>.
Stephanie Link, chief investment officer and portfolio manager at Hightower Advisors, is optimistic about the market&#8217;s prospects if tariff concerns can be averted.
&#8220;I think the biggest surprise is that the Atlanta Fed [GDPNow] is at 2.3% in the face of everything,&#8221; Link wrote on Thursday. &#8220;Consumer continues to spend — Walmart is proof of that. Labor market remains solid and inflation is coming down albeit slowly. EPS up 12% is impressive as well. Get through tariffs and we'll start to focus on more positive things — lower taxes and deregulation.&#8221;
Link noted two contrarian plays she is bullish on as 2025 enters its second half. She called Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) her &#8220;favorite stock for 2025&#8221; amid the company&#8217;s turnaround under new leadership. While the Arlington, Virginia-based company&#8217;s shares have fallen from all-time highs due to regulatory woes and safety concerns, its stock is up over 20% in 2025.
Link also highlighted private equity giant KKR &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) as a firm benefiting from several positive trends.
&#8220;Added KKR this past week [with] the stock down 15% ytd and a play on growth, real assets, infrastructure and fee growth,&#8221; Link said.
She noted Quanta Services Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>), Eaton Corporation PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) and Rockwell Automation Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) as other infrastructure plays.
Also Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45439079/powell-signals-fed-may-shift-its-inflation-strategy-after-5-year-economic-shake-up">Powell Signals Fed May Shift Inflation Strategy After 5 Years Of Economic Upheaval</a></li>
</ul>
Photo: Shutterstock

Equities

Hedge Funds

Exclusives

'My Favorite Stock For 2025,' Says Portfolio Manager, Who Also Notes Two Contrarian Plays During Growth Optimism

Femto Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FMTO#NASDAQ">FMTO</a>) reported quarterly losses of $(2.50 thousand) per share. The company reported $141.20 thousand in sales this quarter.

Earnings

News

FMTO

Femto Technologies Q1 EPS $(2.50K), Sales $141.20K

Pasithea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) reported quarterly losses of $(1.61) per share. This is a 56.49 percent increase over losses of $(3.70) per share from the same period last year.

KTTA

Pasithea Therapeutics Q1 EPS $(1.61) Up From $(3.70) YoY

Vincerx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) reported quarterly losses of $(1.40) per share. This is a 87.93 percent increase over losses of $(11.60) per share from the same period last year.

VINC

Vincerx Pharma Q1 EPS $(1.40) Up From $(11.60) YoY

HOOKIPA Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOK#NASDAQ">HOOK</a>) reported quarterly losses of $(1.23) per share which missed the analyst consensus estimate of $(0.62) by 98.39 percent. This is a 211.82 percent decrease over earnings of $1.10 per share from the same period last year. The company reported quarterly sales of $2.00 million which missed the analyst consensus estimate of $3.38 million by 40.62 percent. This is a 94.52 percent decrease over sales of $36.60 million the same period last year.

Earnings Misses

HOOK

HOOKIPA Pharma Q1 EPS $(1.23) Misses $(0.62) Estimate, Sales $2.00M Miss $3.38M Estimate

Safety Shot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOT#NASDAQ">SHOT</a>) reported quarterly losses of $(0.08) per share. This is a 75.76 percent increase over losses of $(0.33) per share from the same period last year. The company reported $42.10 thousand in sales this quarter. This is a 75.34 percent decrease over sales of $170.73 thousand the same period last year.

SHOT

Safety Shot Q1 EPS $(0.08) Up From $(0.33) YoY, Sales $42.10K Down From $170.73K YoY

Momentus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTS#NASDAQ">MNTS</a>) reported quarterly losses of $(1.64) per share. This is a 82.25 percent increase over losses of $(9.24) per share from the same period last year. The company reported $322.00 thousand in sales this quarter. This is a 37.23 percent decrease over sales of $513.00 thousand the same period last year.

MNTS

Momentus Q1 EPS $(1.64) Up From $(9.24) YoY, Sales $322.00K Down From $513.00K YoY

Franklin Wireless (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FKWL#NASDAQ">FKWL</a>) reported quarterly losses of $(0.05) per share. This is a 50 percent increase over losses of $(0.10) per share from the same period last year. The company reported $8.01 million in sales this quarter. This is a 29.70 percent increase over sales of $6.18 million the same period last year.

FKWL

Franklin Wireless Q3 EPS $(0.05) Up From $(0.10) YoY, Sales $8.01M Up From $6.18M YoY

GT Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.64) by 48.44 percent. This is a 79.88 percent increase over losses of $(1.64) per share from the same period last year.

Earnings Beats

GTBP

GT Biopharma Q1 EPS $(0.33) Beats $(0.64) Estimate

HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) reported quarterly losses of $(0.05) per share. This is a 75 percent increase over losses of $(0.20) per share from the same period last year. The company reported $5.07 thousand in sales this quarter. This is a 99.55 percent decrease over sales of $1.13 million the same period last year.

HCWB

HCW Biologics Q1 EPS $(0.05) Up From $(0.20) YoY, Sales $5.07K Down From $1.13M YoY

Teva Pharmaceuticals (NYSE and TASE: TEVA)&nbsp;today announced that Moody's Investor Services ("Moody's") has raised the company's corporate credit rating to Ba1, outlook stable; from Ba2, outlook positive.

Analyst Ratings

Trading Ideas

TEVA

Teva Pharmaceuticals Announced That Moody's Investor Services Has Raised The Company's Corporate Credit Rating To Ba1, Outlook Stable From Ba2, Outlook Positive

Jones Soda (OTC:<a class="ticker" href="https://www.benzinga.com/stock/JSDA#OTC">JSDA</a>) reported quarterly losses of $(0.01) per share. This is unchanged from the same period last year. The company reported $4.61 million in sales this quarter. This is a 7.82 percent decrease over sales of $5.00 million the same period last year.

JSDA

Jones Soda Q1 EPS $(0.01), Same YoY, Sales $4.61M Down From $5.00M YoY

Pioneer Power Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPSI#NASDAQ">PPSI</a>) affirms FY2025 sales outlook from $27.00 million-$29.00 million to $27.00 million-$29.00 million vs $27.79 million estimate.

Guidance

PPSI

Pioneer Power Solutions Affirms FY2025 Sales Guidance of $27.00M-$29.00M vs $27.79M Est

— Company Estimates Revenue Growth of 40%+ in Q1'25 —
— Company Reiterates Plans to Issue Final Q1'25 Results on May 20, 2025 —
Evolv Technologies Holdings, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>), a leading security technology company pioneering AI-based solutions designed to help create safer experiences, today provided an update on its preliminary financial results for the first quarter of 2025 as well as its upcoming plans to file its related Quarterly Report on Form 10-Q with the Securities and Exchange Commission.
Company Provides Preliminary Update for First Quarter of 2025
The Company today provided an update on preliminary results for the first quarter of 2025. Based on preliminary estimates which are subject to change, the Company expects total revenue to be between approximately $31.0 million and $32.0 million, compared to total revenue of $22.2 million in the first quarter of 2024. The Company expects less than $0.1 million of revenue to be related to the restatement previously completed by the Company. As previously disclosed, as of March 31, 2025, the Company had total cash, cash equivalents, and marketable securities of $35 million, with no outstanding debt. The Company will release final financial results for the first quarter of 2025 on Tuesday, May 20, 2025, after the market closes. Members of the Company's management team plan to host a live webcast at 4:30 p.m. Eastern Time on that day to discuss the financial results as well as management's outlook for the business. The conference call will be webcast live at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fir.evolvtechnology.com&amp;esheet=54255829&amp;newsitemid=20250515290964&amp;lan=en-US&amp;anchor=http%3A%2F%2Fir.evolvtechnology.com&amp;index=1&amp;md5=e090a672c321cba1771ef1925825cbe4">http://ir.evolvtechnology.com</a>.

EVLV

Evolv Technologies Estimates 40%+ Revenue Growth Between $31M - $32M In Q1 2025, Maintains $35M In Cash With No Debt, And Will Release Final Results On May 20, 2025

General

Foot Locker Faces A Potential $59.5M Termination Fee If It Ends The Merger Under Certain Conditions, Such As Changing Its Board Recommendation Or Signing A Superior Deal; Dick's Sporting Goods Risks Owing Foot Locker $95.5M If The Merger Is Terminated Due To Failure To Secure Required Antitrust Approvals

Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) reported quarterly losses of $(0.51) per share.

MOLN

CORRECTION: Molecular Partners Q1 EPS $(0.51)

XChange TEC. Inc. Receives Nasdaq Delisting Determination Letter

Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) reported quarterly losses of $(0.28) per share. This is a 173.68 percent decrease over earnings of $0.38 per share from the same period last year.

ENTO

Entero Therapeutics Q1 GAAP EPS $(0.28) Down From $0.38 YoY

7 analysts have shared their evaluations of IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for IBM, presenting an average target of $261.29, a high estimate of $300.00, and a low estimate of $170.00. Observing a 0.55% increase, the current average has risen from the previous average price target of $259.86. 
<img src="https://www.benzinga.com/files/images/story/2025/1747346488_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of IBM by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Swanson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$285.00</td>
<td>$276.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>David Vogt</td>
<td>UBS</td>
<td>Raises</td>
<td>Sell</td>
<td>$170.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Erik Woodring</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$233.00</td>
<td>$237.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Matthew Swanson</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$276.00</td>
<td>$276.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$265.00</td>
<td>$270.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to IBM. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of IBM compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for IBM's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of IBM's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/IBM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on IBM analyst ratings.</a>
<h2>All You Need to Know About IBM</h2>
IBM looks to be a part of every aspect of an enterprise's IT needs. The company primarily sells software, IT services, consulting, and hardware. IBM operates in 175 countries and employs approximately 300,000 people. The company has a robust roster of business partners to service its clients, which include 95% of all Fortune 500 companies. Primary products include its mainframes, Red Hat software, transaction processing software, and IT consulting.
<h3>A Deep Dive into IBM's Financials</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Positive Revenue Trend: Examining IBM's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 0.55% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: IBM's net margin excels beyond industry benchmarks, reaching 7.26%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): IBM's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.89% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.75%, the company showcases effective utilization of assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.49, caution is advised due to increased financial risk.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 7 Analyst Ratings Have To Say About IBM

Ratings for FS KKR Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSK#NYSE">FSK</a>) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $20.12, a high estimate of $22.00, and a low estimate of $18.00. Observing a downward trend, the current average is 5.32% lower than the prior average price target of $21.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1747346475_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A clear picture of FS KKR Capital's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kenneth Lee</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Mitchel Penn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Perform</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Finian O'Shea</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Paul Johnson</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Finian O'Shea</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$19.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Paul Johnson</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$22.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Kenneth Lee</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$22.00</td>
<td>$21.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to FS KKR Capital. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of FS KKR Capital compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of FS KKR Capital's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of FS KKR Capital's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/FSK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on FS KKR Capital analyst ratings.</a>
<h2>Delving into FS KKR Capital's Background</h2>
FS KKR Capital Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The company's portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies.
<h3>Breaking Down FS KKR Capital's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining FS KKR Capital's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -27.57% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: FS KKR Capital's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 89.55% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): FS KKR Capital's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 1.82%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.82%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: FS KKR Capital's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.22.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

8 Analysts Assess FS KKR Capital: What You Need To Know

Press Releases

Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Health Care

Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025

Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference

Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

Comments

Corbus Pharmaceuticals

Actualités

Dernières nouvelles pour Corbus Pharmaceuticals (NASDAQ:CRBP) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL